Stay updated on Nivolumab for HTLV-Associated T-Cell Leukemia/Lymphoma Clinical Trial

Sign up to get notified when there's something new on the Nivolumab for HTLV-Associated T-Cell Leukemia/Lymphoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nivolumab for HTLV-Associated T-Cell Leukemia/Lymphoma Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The page changes from a 403 error screen to the ClinicalTrials.gov record for the nivolumab Phase II study, displaying its study details, eligibility criteria, locations, and outcome measures.
    Difference
    61%
    Check dated 2026-11-11T02:14:49.000Z thumbnail image
  2. Check
    9 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.2 to v3.8.0.
    Difference
    0.2%
    Check dated 2026-11-04T01:01:05.000Z thumbnail image
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    An NIH-wide notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision identifier changes from v3.7.1 to v3.7.2.
    Difference
    1%
    Check dated 2026-10-21T00:54:02.000Z thumbnail image
  5. Check
    37 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-07T01:00:44.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page that previously displayed the study record for NCT02631746 now shows a 403 Forbidden error, indicating restricted access to the ClinicalTrials.gov entry; this reflects an access issue rather than a substantive content update.
    Difference
    20%
    Check dated 2026-09-23T01:06:28.000Z thumbnail image
  7. Check
    58 days ago
    Change Detected
    Summary
    The page revision tag changed from v3.6.6 to v3.7.0. This indicates a new published iteration of the study record and reflects an update cycle rather than substantive content changes.
    Difference
    0.1%
    Check dated 2026-09-16T00:38:13.000Z thumbnail image

Stay in the know with updates to Nivolumab for HTLV-Associated T-Cell Leukemia/Lymphoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nivolumab for HTLV-Associated T-Cell Leukemia/Lymphoma Clinical Trial page.